{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-019607","form_type":"8-K","ticker":"CORT","cik":"0001088856","company_name":"CORCEPT THERAPEUTICS INC","filed_at":"2024-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.235331+00:00","generated_at":"2026-06-03T01:57:38.631504+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Corcept Q1 revenue up 39% to $146.8M; raises FY2024 guidance to $620-650M","bullets":["Revenue $146.8M (+39% YoY); diluted EPS $0.25 vs $0.14; net income $27.8M.","2024 revenue guidance raised to $620-650M from $600-630M.","Cash and investments $451.0M at March 31, 2024.","GRACE open-label phase showed significant improvements; NDA for relacorilant in Cushing's expected this quarter.","Enrollment completed in GRADIENT, CATALYST, ROSELLA, DAZALS; data expected by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-019607","json":"https://secwatch.observer/filing/0001628280-24-019607.json","markdown":"https://secwatch.observer/filing/0001628280-24-019607.md","text":"https://secwatch.observer/filing/0001628280-24-019607.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1088856/000162828024019607/0001628280-24-019607-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1088856/000162828024019607/cort-20240501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T01:57:38.631504+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}